InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Summary

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.

* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.
* The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Conditions

• Cancer Risk
• Cancer Predisposition Syndrome
• Hereditary Cancer Prediction
• Childhood Cancer Survivors
• Adult Cancer Survivors
• IARC Carcinogens
• Smoking History
• Lung Cancer
• Ductal/Lobular Carcinoma
• Barrett Esophagus
• Pancreatic Precursor Lesions
• Colonic Dysplasia/Adenomata
• Non-Alcoholic Fatty Liver Disease
• Non Alcoholic Steatohepatitis
• Cirrhosis
• High Grade Prostatic Epithelial Neoplasia
• High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ
• Adenomatous Hyperplasia
• High-risk Oral Precancerous Diseases
• Melanocytic Lesion, Adult
• Hematologic Malignancy
• Lung; Node
• Serous Tubal Intraepithelial Carcinoma
• Endometrial Intraepithelial Neoplasia
• Cervical and Endocervical Carcinoma in Situ
• Vulvar Intraepithelial Neoplasia
• Nephrogenic Rests
• Benign Bone Lesions With Risk of Malignant Degeneration
• Giant Cell Tumor
• Osteochondroma
• Spitz Nevus

Interventions

OTHER

Samples

Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues

Sponsors & Collaborators

• Dana-Farber Cancer Institute

  lead OTHER

Principal Investigators

• Sapna Syngal, MD · Dana-Farber Cancer Institute

Eligibility

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-04-25

Primary Completion

2027-03-25

Completion

2032-03-25

Countries

• United States

Study Locations